摘要
急性髓系白血病患者有异常的、不正常的免疫状态,寻找新的药物靶向途径,为新型靶向药物结合免疫信号,功能并响应铺平了道路。小分子免疫调节药物(IMiDs)是一类来源于母体化合物的药物,沙利度胺。目前有3个小分子免疫调节药物批准用于多种恶性肿瘤:沙利度胺、来那度胺,和新药,pomalidomide。小分子免疫调节药物导致许多免疫生物学效应如细胞因子调节,T细胞共刺激分子的表达下调,共同抑制,增强自然杀伤细胞的活性,调节性T细胞的抑制作用,修复扰动的突触形成T细胞。小分子免疫调节药物已在各种广泛的研究和有前途的临床活动性急性髓系白血病的设置。本文综述了各种小分子免疫调节药物免疫作用,研究各种小分子免疫调节药物急性髓系白血病的理论基础,并发表和正在进行的临床试验调查主要活动在急性髓系白血病。
关键词: 急性髓系白血病,免疫治疗,小分子免疫调节药物,来那度胺,pomalidomide,沙利度胺。
图形摘要
Current Drug Targets
Title:Immunomodulatory Drugs: IMiDs in Acute Myeloid Leukemia (AML)
Volume: 18 Issue: 3
Author(s): Joshua F. Zeidner, Matthew C. Foster.
Affiliation:
关键词: 急性髓系白血病,免疫治疗,小分子免疫调节药物,来那度胺,pomalidomide,沙利度胺。
摘要: AML patients have an aberrant and dysfunctional immune state, paving the way for novel agents targeting pathways that integrate with immune signaling, function, and response. Small molecule immunomodulatory drugs (IMiDs) represent a class of agents derived from the parent compound, thalidomide. There are currently 3 IMiDs approved for a variety of malignancies: thalidomide, lenalidomide, and the newest agent, pomalidomide. IMiDs lead to a multitude of immunobiologic effects such as cytokine modulation, co-stimulation of T cells, down-regulation of co-inhibitory molecules, enhancing natural killer cell activity, inhibition of regulatory T cells, and repairing perturbed synapse formation on T cells. IMiDs have been extensively studied in various AML settings with promising clinical activity. This review discusses the immunologic effects of IMiDs, the rationale for studying IMiDs in AML, and the published and ongoing clinical trials investigating IMiD activity in AML.
Export Options
About this article
Cite this article as:
Joshua F. Zeidner, Matthew C. Foster. , Immunomodulatory Drugs: IMiDs in Acute Myeloid Leukemia (AML), Current Drug Targets 2017; 18 (3) . https://dx.doi.org/10.2174/1389450116666150304104315
DOI https://dx.doi.org/10.2174/1389450116666150304104315 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Related Journals
Related Books
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Targeting BCR-ABL Oncoprotein for Leukemia Therapy: Current Biotechnology and Future Perspectives
Current Biotechnology Pharmacogenetics of Irinotecan Disposition and Toxicity: A Review
Current Clinical Pharmacology Dasatinib in the Treatment of Chronic Myeloid Leukemia
Current Signal Transduction Therapy p53-Induced Apoptosis and Inhibitors of p53
Current Medicinal Chemistry New Immunosuppressants: Immunosuppression and Immunomodulation
Medicinal Chemistry Reviews - Online (Discontinued) Polymer-Based Drug Delivery Systems, Development and Pre-Clinical Status
Current Pharmaceutical Design Bench to Bedside Targeting of FLT3 in Acute Leukemia
Current Drug Targets miR-1271 Regulates Cisplatin Resistance of Human Gastric Cancer Cell Lines by Targeting IGF1R, IRS1, mTOR, and BCL2
Anti-Cancer Agents in Medicinal Chemistry A Dual Role of Cyclin E in Cell Proliferation and Apotosis May Provide a Target for Cancer Therapy
Current Cancer Drug Targets Heat Shock Protein Inhibitors for the Treatment of Fungal Infections
Recent Patents on Anti-Infective Drug Discovery Chemopreventive and Anti-leukemic Effects of Ethanol Extracts of Moringa oleifera Leaves on Wistar Rats Bearing Benzene Induced Leukemia
Current Pharmaceutical Biotechnology Expansion of Umbilical Cord Blood for Clinical Transplantation
Current Stem Cell Research & Therapy Synthetic and Natural Immunomodulators Acting as Interferon Inducers
Current Pharmaceutical Design Biomimetic Drug Delivery Systems Oriented by Biological Function in Tumor Targeting
Current Drug Targets Inflammation and Anemia
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Diagnosis and Management of Lynch Syndrome
Recent Patents on Regenerative Medicine An Updated Review of Natural Products Intended to Prevent or Treat Oral Mucositis in Patients Undergoing Radio-Chemotherapy
Current Pharmaceutical Biotechnology Resveratrol as a Chemopreventive Agent: A Promising Molecule for Fighting Cancer
Current Drug Targets Arginine Deprivation as a Targeted Therapy for Cancer
Current Pharmaceutical Design Potential Gene Therapy Strategies for Cancer Stem Cells
Current Gene Therapy